2^nd International conference on Flu October 31- November 02, 2016
San Francisco, California, USA

Flu Vaccines: Current and Novel Approach

Flu Vaccine is an annual vaccination using a vaccine that is specific for a given year to protect against the highly variable influenza virus. Risk management and effectiveness of vaccines are important for public health. In the United States, NIAID laboratories are developing novel vaccine candidates for seasonal influenza viruses and for avian strains with pandemic potential. In late 2006, the NIAID Vaccine Research Center initiated the first human trial of an investigational DNA vaccine against the H5N1 avian influenza virus, a strain that has infected and continues to threaten humans. In addition, researchers in the NIAID Laboratory of Infectious Diseases are working with MedImmune to generate candidate live-attenuated vaccines for a broad range of influenza subtypes with pandemic potential. To date, five of these vaccine candidates have advanced to Phase I clinical trials. Many Ebola vaccine candidates had been developed in the decade prior to 2014, but none has yet been approved for clinical use in humans.

Flu Vaccine can be defined as a biological preparation that provides active acquired immunity to a flu disease. Flu vaccination by injection, commonly known as the "flu jab" is available every year on the for adults (and some children) at risk of flu and its complications. For improving vaccine immunogenicity adjuvants are used. Vaccine Adjuvants – It can be defined as a component which potentiates the immune system and accelerates the immune responses to an antigen.These components act to induce, prolong, and enhance antigen-specific immune responses when used in combination with specific vaccine antigens.  Aluminum salts are the only licensed adjuvant in the United States, but the combination of these salts with inactivated influenza A/H5N1 antigens has had little effect on seroresponses. Several oil-in-water adjuvants, including MF59 and AS03, have significantly enhanced immune responses in healthy adult vaccine recipients to inactivated influenza A/H5N1.

• Genetic and evolution of virus and host
• Risk management and effectiveness of vaccines
• Targeting strategies for influenza vaccines
• Adjuvants and their improvement issues
• Clinical trails of influenza based vaccines
• Epidemiology and prevention of vaccine
• Ebola Vaccine

Recommended Sessions

Related Journals

Are you interested in